Karuna Therapeutics, Inc. and GFB, LLC, assignee of the Goldfinch Bio assignment estate, today announced their entry into an exclusive license agreement under which Karuna will obtain global ...

Karuna Therapeutics, Inc. Unaudited Consolidated Statements of Operations (in thousands, except share and per share data) Three Months Ended Year Ended December 31, December 31, ...

Karuna Therapeutics focuses on therapies to treat neurological conditions. The stock is up more than 52% over the past year. The company has, as of the fourth quarter, $1.1 billion in cash, it said.

Over the past 3 months, 8 analysts have published their opinion on Karuna Therapeutics (NASDAQ:KRTX) stock. These analysts are typically employed by large Wall Street banks and tasked with ...

Karuna Therapeutics, Inc. (NASDAQ:KRTX) has a market capitalization of $6.334 billion. ClearBridge SMID Cap Growth Strategy made the following comment about Karuna Therapeutics, Inc. (NASDAQ:KRTX ...

Karuna Therapeutics stock jumped 48% into record territory early Friday, after the biopharmaceutical company announced a $14 billion agreement to be bought by Bristol Myers Squibb.

Drugmaker Bristol Myers BMY-0.83%decrease; red down pointing triangle Squibb reached a deal to buy neuroscience-drug developer Karuna Therapeutics for $14 billion. Under the terms, Bristol would ...

The team behind Karuna Therapeutics, the Boston biotech that was bought by drug giant Bristol Myers Squibb in a $14 billion deal in December, launched another company on Tuesday called Seaport ...

I recommended Karuna Therapeutics, Inc. in 2022 before the Phase 3 data for KarXT in treating schizophrenia. The stock reached a peak of $290 (165% gain) after ...

Karuna Therapeutics. Karuna Therapeutics is a clinical-stage biotech headquartered in Boston, MA, founded back in July 2009 by Andrew Miller, Eric Elenko, and Peter Jeffrey Conn.The company ...

Analysts have provided the following ratings for Karuna Therapeutics (NASDAQ:KRTX) within the last quarter: These 12 analysts have an average price target of $281.25 versus the current price of ...

Drugmaker Bristol Myers Squibb is acquiring Karuna Therapeutics, a biopharmaceutical company that has developed a new antipsychotic, in a $14 billion deal.